|
Novartis delivered solid Q1 despite Gleevec loss of exclusivity
|
21 April 2016 |
|
Novartis shareholders approve all resolutions proposed by Board of Directors
|
23 February 2016 |
|
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
|
18 February 2016 |
|
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
|
11 February 2016 |
|
Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
|
15 January 2016 |
|
Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
|
05 January 2016 |
|
300 million child-friendly antimalarial treatments supplied without profit by Novartis
|
09 December 2015 |
|
Novartis Foundation and partners launch new hypertension program in Ghana
|
29 October 2015 |
|
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
|
21 October 2015 |
|
Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
|
15 October 2015 |